Metronidazole Triple Therapy for H. pylori After Clarithromycin Failure
Author Information
Author(s): Lee Chang-Min, Kim Seong-Je, Choi Jung-Woo, Cho Hyun-Chin, Lee Ok-Jae, Maeda Shin
Primary Institution: Gyeongsang National University Hospital
Hypothesis
This study aims to determine the efficacy of metronidazole triple therapy as a second-line regimen for H. pylori eradication after failure of clarithromycin triple therapy.
Conclusion
Metronidazole triple therapy could be a viable second-line treatment option for H. pylori eradication after clarithromycin failure, especially in patients under 70 years old.
Supporting Evidence
- The eradication rate of metronidazole triple therapy was 74.8% in intention-to-treat analysis.
- The eradication rate of bismuth quadruple therapy was 79.7% in intention-to-treat analysis.
- 71.4% of patients who failed metronidazole therapy were successfully treated with bismuth quadruple therapy as a third-line option.
- Overall eradication rates were 99.2% for metronidazole and 98.2% for bismuth quadruple therapy after all treatments.
Takeaway
This study looked at how well a simple treatment using metronidazole works for a stomach bug after another treatment didn't work. It found that it can be a good option for many people.
Methodology
The study was a retrospective analysis of medical records from patients treated for H. pylori infection after failure of first-line clarithromycin therapy.
Potential Biases
There may be selection bias due to differences in patient demographics between treatment groups.
Limitations
The study was retrospective, had a single-center design, and may not be representative of all regions in Korea.
Participant Demographics
The study included adult patients with H. pylori infection, with a mean age of approximately 59.8 years.
Statistical Information
P-Value
0.287
Statistical Significance
p = 0.287
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website